300529SZSE
🚨 Material Event

Announcement on the Preliminary Trigger of Downward Adjustment of Convertible Bond Conversion Price

Jafron Biomedical Co., Ltd.··6 pages

✨ AI Summary

This announcement from Jianfan Bio-Tech warns that the company's stock price has fallen below 85% of the conversion price for ten trading days, potentially triggering a downward adjustment of the convertible bond conversion price. The company will follow its prospectus and relevant regulations to review and disclose any decision on price adjustment. Investors are advised to be aware of investment risks.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300529

Bond Code: 123117

Securities Abbreviation: Jianfan Bio-Tech

Bond Abbreviation: Jianfan Convertible Bond

Announcement Number: 2026-057

Jianfan Bio-Tech Group Co., Ltd.

Announcement on the Preliminary Trigger of Downward Adjustment of Convertible Bond Conversion Price

The Company and all members of its Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Special Reminder:

  1. Securities Code: 300529 Securities Abbreviation: Jianfan Bio-Tech

  2. Bond Code: 123117 Bond Abbreviation: Jianfan Convertible Bond

  3. Conversion Price: 38.15 RMB/share

  4. Conversion Period: December 29, 2021 to June 22, 2027

  5. According to the Company's "Prospectus for the Offering of Convertible Corporate Bonds to Non-specific Targets on the ChiNext Market by Jianfan Bio-Tech Group Co., Ltd." (hereinafter referred to as the "Prospectus"), during the term of the convertible bonds, if the closing price of the company's stock is lower than 85% of the current conversion price for at least fifteen trading days within any consecutive thirty trading days, the Company's Board of Directors has the right to propose a downward adjustment plan for the conversion price and submit it to the Company's shareholders' meeting for consideration.

From August 10, 2026, to August 21, 2026, the company's stock has had ten trading days below 85% of the current conversion price. If the conditions for adjusting the conversion price are triggered, the Company will fulfill the subsequent deliberation procedures and information disclosure obligations in a timely manner as stipulated in the "Prospectus." We kindly remind investors to pay attention to investment risks.

I. Basic Information of Convertible Corporate Bonds

(I) Issuance of Convertible Bonds

With the approval of the China Securities Regulatory Commission's "Zheng Jian Xu Ke [2020] No. 3617" document, Jianfan Bio-Tech Group Co., Ltd. issued 10,000,000 convertible corporate bonds to non-specific targets on June 23, 2021. Each bond has a face value of RMB 100, and the total issuance amount is RMB 1,000,000,000. The convertible bonds issued to non-specific targets were first preferentially allocated to original shareholders registered at the close of the equity registration date. The remaining portion after the preferential allocation to original shareholders (including the portion abandoned by original shareholders) was offered to the public through online issuance via the Shenzhen Stock Exchange trading system. The underwriting syndicate will underwrite any portion not subscribed up to RMB 1,000,000,000.

(II) Listing of Convertible Bonds

With the approval of the Shenzhen Stock Exchange, the Company's RMB 1,000,000,000 convertible corporate bonds were listed and traded on the Shenzhen Stock Exchange on July 12, 2021. The bond abbreviation is "Jianfan Convertible Bond," and the bond code is "123117."

(III) Conversion Period of Convertible Bonds

According to the "Listing Rules for the ChiNext Market of the Shenzhen Stock Exchange" and other relevant regulations and the provisions of the "Prospectus," the conversion period for this convertible corporate bond shall be from the first trading day six months after the issuance completion date (June 29, 2021) to the maturity date of the convertible corporate bond, i.e., from December 29, 2021, to June 22, 2027.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.